Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Kamada ( (IL:KMDA) ).
Kamada Ltd. announced a $25 million three-year contract to supply its specialty immune globulin products, KAMRAB® and VARIZIG®, in Latin America from 2025 to 2027. This agreement underscores Kamada’s global market strength and supports its growth outlook while highlighting the commercial potential of its product portfolio in international markets beyond the U.S. and Canada.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in plasma-derived products for rare and serious conditions. It focuses on diseases with limited treatment alternatives and has a portfolio that includes six FDA-approved biopharmaceutical products. Kamada operates a plasma collection center in Texas and distributes products in over 30 countries, leveraging its expertise and presence in the Israeli market.
YTD Price Performance: 11.85%
Average Trading Volume: 77,954
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $408M
See more insights into KMDA stock on TipRanks’ Stock Analysis page.
